WO2001000231A3 - Use of cpg as an adjuvant for malaria vaccine - Google Patents

Use of cpg as an adjuvant for malaria vaccine Download PDF

Info

Publication number
WO2001000231A3
WO2001000231A3 PCT/EP2000/005841 EP0005841W WO0100231A3 WO 2001000231 A3 WO2001000231 A3 WO 2001000231A3 EP 0005841 W EP0005841 W EP 0005841W WO 0100231 A3 WO0100231 A3 WO 0100231A3
Authority
WO
WIPO (PCT)
Prior art keywords
cpg
adjuvant
malaria vaccine
vaccine
administration
Prior art date
Application number
PCT/EP2000/005841
Other languages
French (fr)
Other versions
WO2001000231A2 (en
Inventor
Joseph Cohen
Nathalie Garcon
Gerald Voss
Original Assignee
Smithkline Beecham Biolog
Joseph Cohen
Nathalie Garcon
Gerald Voss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog, Joseph Cohen, Nathalie Garcon, Gerald Voss filed Critical Smithkline Beecham Biolog
Priority to EP00945810A priority Critical patent/EP1198243A2/en
Priority to AU59777/00A priority patent/AU5977700A/en
Priority to CA002376926A priority patent/CA2376926A1/en
Publication of WO2001000231A2 publication Critical patent/WO2001000231A2/en
Publication of WO2001000231A3 publication Critical patent/WO2001000231A3/en
Priority to HK02107137.7A priority patent/HK1047034A1/en
Priority to US11/934,814 priority patent/US20080131464A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A vaccine formulation for the prevention or amelioration of plasmodium infection in humans is provided. The vaccine comprises a malaria antigen, especially a protein which comprises a portion of the CS protein of P. falciparum fused in frame via a linear linker to the N-terminal of HBsAg, and an immunostimulatory CpG oligonucleotide. Methods for making the vaccine formulation of the invention are described. Patients may also be treated by pre-administration of the CpG oligonucleotide prior to administration of the malaria antigen.
PCT/EP2000/005841 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine WO2001000231A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00945810A EP1198243A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine
AU59777/00A AU5977700A (en) 1999-06-29 2000-06-23 Vaccines
CA002376926A CA2376926A1 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine
HK02107137.7A HK1047034A1 (en) 1999-06-29 2002-09-26 Use of cpg as an adjuvant for malaria vaccine
US11/934,814 US20080131464A1 (en) 1999-06-29 2007-11-05 Vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9915204.3 1999-06-29
GBGB9915204.3A GB9915204D0 (en) 1999-06-29 1999-06-29 Vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/789,758 Continuation US20050002958A1 (en) 1999-06-29 2004-02-27 Vaccines

Publications (2)

Publication Number Publication Date
WO2001000231A2 WO2001000231A2 (en) 2001-01-04
WO2001000231A3 true WO2001000231A3 (en) 2001-07-05

Family

ID=10856286

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/005841 WO2001000231A2 (en) 1999-06-29 2000-06-23 Use of cpg as an adjuvant for malaria vaccine

Country Status (6)

Country Link
EP (1) EP1198243A2 (en)
AU (1) AU5977700A (en)
CA (1) CA2376926A1 (en)
GB (1) GB9915204D0 (en)
HK (1) HK1047034A1 (en)
WO (1) WO2001000231A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69932717T2 (en) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
CA2462946C (en) * 2001-01-26 2014-04-29 Jeffrey A. Lyon Recombinant p. falciparum merozoite protein-142 vaccine
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
JP2005510462A (en) * 2001-08-10 2005-04-21 ダイナバックス テクノロジーズ コーポレイション Production of immunomodulating oligonucleotides and methods of use thereof
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
AU2003263212A1 (en) * 2002-08-14 2004-03-03 Avidis Sa Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use
JP4199988B2 (en) * 2002-11-14 2008-12-24 大日本印刷株式会社 Decorative sheet
NZ575273A (en) 2006-09-07 2012-02-24 Glaxosmithkline Biolog Sa Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1998005355A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1999011241A1 (en) * 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
WO2000023105A2 (en) * 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228698T2 (en) * 1991-11-16 1999-09-16 Smithkline Beecham Biolog HYBRID PROTEIN BETWEEN PLASMODIUM AND HBsAG

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
WO1998005355A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) * 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
WO1999011241A1 (en) * 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
WO2000023105A2 (en) * 1998-10-16 2000-04-27 Smithkline Beecham Biologicals S.A. Adjuvant systems and vaccines
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JONES T R ET AL: "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 17, no. 23-24, 6 August 1999 (1999-08-06), pages 3065 - 3071, XP004173617, ISSN: 0264-410X *

Also Published As

Publication number Publication date
EP1198243A2 (en) 2002-04-24
AU5977700A (en) 2001-01-31
CA2376926A1 (en) 2001-01-04
WO2001000231A2 (en) 2001-01-04
HK1047034A1 (en) 2003-02-07
GB9915204D0 (en) 1999-09-01

Similar Documents

Publication Publication Date Title
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
AU784403B2 (en) Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
WO2002028428A3 (en) Vaccine composition
WO2002034205A3 (en) Using heat shock proteins to increase immune response
IL145982A0 (en) Vaccines
WO1999033488A3 (en) Adjuvanted vaccine formulation
UA93508C2 (en) Anti-malaria vaccine
WO2001000231A3 (en) Use of cpg as an adjuvant for malaria vaccine
WO2001092470A3 (en) Dna expression vectors and methods of use
WO2000050006A3 (en) Microemulsions with adsorbed macromoelecules and microparticles
LU91328I2 (en) Human papillomavirus vaccine Ätypes 6,11,16,18Ü (recombinant, adsorbed)
WO2003039595A3 (en) Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
WO2001068129A3 (en) Adjuvant for vaccines
WO2002087494A3 (en) Novel vaccine
WO2002028426A8 (en) Split enveloped virus preparation
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
WO2001037869A9 (en) Vaccine compositions
HK1063726A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2003059385A3 (en) Hiv vaccine and method of use
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
WO2003090687A3 (en) Using heat shock proteins to increase immune response
MXPA02010173A (en) Leishmania.
EP0289110A3 (en) Conjugate malaria vaccine
WO2002022687A3 (en) Viral chemokine-tumur antigen fusion proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000945810

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2376926

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10018704

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000945810

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP